Enrollment exceeding expectations in DURAVYU™ Phase 3 wet AMD clinical trials with LUGANO over 50% enrolled and LUCIA recruiting ahead of schedule – – Positive Phase 2 VERONA clinical trial of DURAVYU ...

EyePoint Pharmaceuticals also highlights its state-of-the-art cGMP manufacturing facility in Northbridge, MA, which is ready ...

The approvals for Celltrion's denosumab-bmwo (Stoboclo and Osenvelt) mark the third FDA green light for a biosimilar to treat ...

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.

Q4 2024 Earnings Call Transcript March 3, 2025 Ocular Therapeutix, Inc. misses on earnings expectations. Reported EPS is ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and ...

Adverum Biotechnologies (ADVM) announced the initiation of the ARTEMIS Phase 3 study. This pivotal trial is designed to evaluate the efficacy ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and improve vision outcomes for patients with wet AMDARTEMIS ...

Older patients with diabetic macular edema have a weaker response to anti-VEGF treatment, according to a presentation at ...

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart biosimilar.